Literature DB >> 9698114

Cisplatin-treated macrophages produce oncostatin M: regulation by serine/threonine and protein tyrosine kinases/phosphatases and Ca2+/calmodulin.

R A Singh1, A Sodhi.   

Abstract

In the present study it was investigated whether cisplatin-treated murine peritoneal macrophages produce oncostatin M (OSM) and what is the underlying mechanism. The culture supernatants of cisplatin-treated macrophages significantly inhibited the proliferation of OSM-sensitive cell line A375. Within 15 min of cisplatin treatment significant OSM was synthesized and secreted by macrophages. Inhibitors of serine/threonine and protein tyrosine phosphatases augmented cisplatin-induced OSM production of macrophages. The protein kinase C and protein tyrosine kinase inhibitors significantly inhibited OSM production of cisplatin-treated macrophages. The OSM production of cisplatin-treated macrophages was also inhibited in the presence of Ca2+ chelators, Ca2+ channel blocker and calmodulin/calmodulin-dependent kinase inhibitors. These data suggest that OSM production of cisplatin-treated macrophages is regulated by opposing actions of phosphatases and kinases. It is also suggested that OSM production of cisplatin-treated macrophages is dependent on Ca2+, calmodulin and calmodulin-dependent kinase.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9698114     DOI: 10.1016/s0165-2478(98)00040-6

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  9 in total

1.  Production of TNF-alpha, IL-1beta, IL-12 and IFN-gamma in murine peritoneal macrophages on treatment with wheat germ agglutinin in vitro: involvement of tyrosine kinase pathways.

Authors:  Ajit Sodhi; Varun Kesherwani
Journal:  Glycoconj J       Date:  2007-08-01       Impact factor: 2.916

2.  STAT3-mediated SMAD3 activation underlies Oncostatin M-induced Senescence.

Authors:  Benjamin L Bryson; Damian J Junk; Rocky Cipriano; Mark W Jackson
Journal:  Cell Cycle       Date:  2016-11-28       Impact factor: 4.534

3.  c-MYC functions as a molecular switch to alter the response of human mammary epithelial cells to oncostatin M.

Authors:  Charlene E Kan; Rocky Cipriano; Mark W Jackson
Journal:  Cancer Res       Date:  2011-10-05       Impact factor: 12.701

4.  Oncostatin M Receptor-Targeted Antibodies Suppress STAT3 Signaling and Inhibit Ovarian Cancer Growth.

Authors:  Anjali Geethadevi; Ajay Nair; Deepak Parashar; Zhiqiang Ku; Wei Xiong; Hui Deng; Yongsheng Li; Jasmine George; Donna M McAllister; Yunguang Sun; Ishaque P Kadamberi; Prachi Gupta; Michael B Dwinell; William H Bradley; Janet S Rader; Hallgeir Rui; Robert F Schwabe; Ningyan Zhang; Sunila Pradeep; Zhiqiang An; Pradeep Chaluvally-Raghavan
Journal:  Cancer Res       Date:  2021-08-11       Impact factor: 12.701

5.  Potent EMT and CSC Phenotypes Are Induced By Oncostatin-M in Pancreatic Cancer.

Authors:  Jacob M Smigiel; Neetha Parameswaran; Mark W Jackson
Journal:  Mol Cancer Res       Date:  2017-01-04       Impact factor: 6.333

6.  HiJAK'd Signaling; the STAT3 Paradox in Senescence and Cancer Progression.

Authors:  Damian J Junk; Benjamin L Bryson; Mark W Jackson
Journal:  Cancers (Basel)       Date:  2014-03-26       Impact factor: 6.639

7.  The opposing effects of interferon-beta and oncostatin-M as regulators of cancer stem cell plasticity in triple-negative breast cancer.

Authors:  Mary R Doherty; Jenny G Parvani; Ilaria Tamagno; Damian J Junk; Benjamin L Bryson; Hyeon Joo Cheon; George R Stark; Mark W Jackson
Journal:  Breast Cancer Res       Date:  2019-04-29       Impact factor: 6.466

Review 8.  Cancer Stem Cell Plasticity Drives Therapeutic Resistance.

Authors:  Mary R Doherty; Jacob M Smigiel; Damian J Junk; Mark W Jackson
Journal:  Cancers (Basel)       Date:  2016-01-05       Impact factor: 6.639

9.  Oncostatin M promotes cancer cell plasticity through cooperative STAT3-SMAD3 signaling.

Authors:  D J Junk; B L Bryson; J M Smigiel; N Parameswaran; C A Bartel; M W Jackson
Journal:  Oncogene       Date:  2017-03-13       Impact factor: 8.756

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.